Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Change in Account Payables: 2015-2025

Historic Change in Account Payables for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Sep 2025 value amounting to -$3.5 million.

  • Syndax Pharmaceuticals' Change in Account Payables rose 47.12% to -$3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year increase of 875.67%. This contributed to the annual value of $1.7 million for FY2024, which is 70.33% down from last year.
  • Syndax Pharmaceuticals' Change in Account Payables amounted to -$3.5 million in Q3 2025, which was down 148.28% from $7.3 million recorded in Q2 2025.
  • In the past 5 years, Syndax Pharmaceuticals' Change in Account Payables registered a high of $7.3 million during Q2 2025, and its lowest value of -$6.7 million during Q3 2024.
  • For the 3-year period, Syndax Pharmaceuticals' Change in Account Payables averaged around $861,455, with its median value being $2.8 million (2024).
  • As far as peak fluctuations go, Syndax Pharmaceuticals' Change in Account Payables skyrocketed by 266.77% in 2021, and later plummeted by 829.29% in 2023.
  • Over the past 5 years, Syndax Pharmaceuticals' Change in Account Payables (Quarterly) stood at $547,000 in 2021, then tumbled by 605.30% to -$2.8 million in 2022, then spiked by 241.53% to $3.9 million in 2023, then soared by 71.98% to $6.7 million in 2024, then surged by 47.12% to -$3.5 million in 2025.
  • Its Change in Account Payables was -$3.5 million in Q3 2025, compared to $7.3 million in Q2 2025 and -$1.6 million in Q1 2025.